Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mach7 Technologies ( (AU:M7T) ) has issued an announcement.
Mach7 Technologies Limited announced a change in the interests of its director, Robert Bazzani, who has acquired an additional 100,000 fully paid ordinary shares through on-market purchases. This acquisition increases Bazzani’s total holding to 354,728 shares, reflecting a strategic move that may signal confidence in the company’s growth prospects and potentially impact stakeholder perceptions positively.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.81 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies Limited operates in the technology sector, focusing on providing innovative software solutions for healthcare enterprises. The company specializes in developing enterprise imaging platforms that enhance the management and sharing of medical images and data, aiming to improve clinical and operational efficiencies for healthcare providers.
Average Trading Volume: 223,485
Technical Sentiment Signal: Sell
Current Market Cap: A$71.67M
Find detailed analytics on M7T stock on TipRanks’ Stock Analysis page.